Back
Also listed as
ALBHF
OTC
Day Range
$15.32
$15.50
52-Week Range
$8.95
$19.45
Volume
500
50D / 200D Avg
$15.86
/
$14.68
Prev Close
$15.50
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 8.7 | 0.4 |
| P/B | 0.8 | 2.9 |
| ROE % | 9.3 | 3.9 |
| Net Margin % | 4.7 | 3.8 |
| Rev Growth 5Y % | 18.5 | 10.0 |
| D/E | 0.0 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2027 |
$0.00
$0.00 – $0.00
|
40 B | 0 |
| FY2026 |
$0.00
$0.00 – $0.00
|
35 B | 0 |
Key Takeaways
Revenue grew 18.50% annually over 5 years — strong growth
Earnings grew 62.14% over the past year
Debt/Equity of 0.00 — conservative balance sheet
Generating 1.38B in free cash flow
P/E of 8.72 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 5.28%
Growth
Revenue Growth (5Y)
18.50%
Revenue (1Y)13.22%
Earnings (1Y)62.14%
FCF Growth (3Y)134.58%
Quality
Return on Equity
9.28%
ROIC7.23%
Net Margin4.68%
Op. Margin5.15%
Safety
Debt / Equity
0.00
Current Ratio2.59
Interest Coverage604.09
Valuation
P/E Ratio
8.72
P/B Ratio0.77
EV/EBITDA6.54
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 13.22% | Revenue Growth (3Y) | 6.93% |
| Earnings Growth (1Y) | 62.14% | Earnings Growth (3Y) | 63.53% |
| Revenue Growth (5Y) | 18.50% | Earnings Growth (5Y) | 42.38% |
| Profitability | |||
| Revenue (TTM) | 30.60B | Net Income (TTM) | 1.43B |
| ROE | 9.28% | ROA | 6.76% |
| Gross Margin | 24.29% | Operating Margin | 5.15% |
| Net Margin | 4.68% | Free Cash Flow (TTM) | 1.38B |
| ROIC | 7.23% | FCF Growth (3Y) | 134.58% |
| Safety | |||
| Debt / Equity | 0.00 | Current Ratio | 2.59 |
| Interest Coverage | 604.09 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 8.72 | P/B Ratio | 0.77 |
| P/S Ratio | 0.41 | PEG Ratio | 1.16 |
| EV/EBITDA | 6.54 | Dividend Yield | 0.00% |
| Market Cap | 12.50B | Enterprise Value | 10.31B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 30.60B | 27.03B | 26.76B | 20.58B | 15.52B |
| Net Income | 1.43B | 883.48M | 535.65M | -265.56M | 348.59M |
| EPS (Diluted) | 1.78 | 1.25 | 0.79 | -0.39 | 0.52 |
| Gross Profit | 7.43B | 5.90B | 5.70B | 4.11B | 3.62B |
| Operating Income | 1.58B | 640.18M | -31.79M | -1.10B | 58.56M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 21.18B | 19.71B | 20.75B | 19.20B | 17.74B |
| Total Liabilities | 4.87B | 5.19B | 5.60B | 5.13B | 3.46B |
| Shareholders' Equity | 16.31B | 14.54B | 15.17B | 14.10B | 14.30B |
| Total Debt | 35.52M | 82.17M | 77.80M | 135.41M | 37.74M |
| Cash & Equivalents | 2.22B | 3.49B | 10.92B | 10.55B | 11.64B |
| Current Assets | 12.28B | 13.51B | 14.91B | 13.57B | 14.20B |
| Current Liabilities | 4.74B | 5.03B | 5.44B | 4.82B | 3.40B |
Strategy Scores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026
Entered
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered
Defensive Investing (Benjamin Graham)
Mar 24, 2026